

📍 Europe



(<https://europe.medtronic.com/xd-en/index.html>)
for femoropopliteal disease

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter is a clinically proven primary endovascular therapy that treats femoropopliteal disease. It is indicated for *de novo*, restenotic, or in-stent restenotic lesions up to 360 mm, with reference vessel diameters of 4 to 7 mm.

DOWNLOAD BROCHURE (OPENS NEW WINDOW)

(/CONTENT/DAM/COVIDIEN/LIBRARY/EMEA/MYSOURCE/PRODUCTS/CARDIAC-VASCULAR/CARDIOVASCULAR/PTA-BALLOONS/IN-PACT-ADMIRAL-BROCHURE.PDF)

▲ Indications, Safety, and Warnings (<https://europe.medtronic.com/xd-en/healthcare-professionals/cvg-emea-indications-safety-warnings.html>)

Tested. Trusted.

The IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter remains the market-leading DCB, backed by five years of efficacy data,¹ even in complex lesions.²

See the data (<https://europe.medtronic.com/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/clinical-outcomes.html>)

Maintain long-term vessel patency with the IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter, which provides durable, consistent, and safe outcomes across multiple clinical trials, as well as across complex patient and lesion types. With more than 3,500 patients enrolled in 21 clinical studies and 500,000+ patients treated worldwide, the IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter is the best-selling DCB on the market for treatment of femoropopliteal disease.

Proven formulation of paclitaxel in tissue


Only the IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter releases the drug into the tissue through the restenotic window.

Duration of paclitaxel in tissue[†]

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter, with drug in tissue up to 180 days,³ has the:

- **Highest** patency benefit through three years compared to PTA^{‡1}
- **Lowest** CD-TLR rate through five years¹
- **Most** publications for a DCB[§]

View clinical data (<https://europe.medtronic.com/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/performance.html>)



coated PTA Balloon Catheter mechanism of action

IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter

Feature	Specifications
Paclitaxel drug dose	3.5 µg/mm ²
Excipient	Urea
Balloon diameters	4.0 to 7.0 mm
Balloon lengths	40, 60, 80, 120, 150, 200, and 250 mm ^{II}
Balloon fold configurations	4.0 mm: 3 folds; 5.0, 6.0, and 7.0 mm: 6 folds
Catheter design	Over-the-wire (OTW)
Catheter lengths	40, 80 and 130 cm
Guidewire compatibility	0.035 in

Ref. Number Usable Length 40cm	Ref. Number Usable Length 80cm	Ref. Number Usable Length 130cm	Balloon Diameter (mm)	Balloon length (mm)	Recommended introducer sheath (F)	RBP (atm)
SBI 040 040 04P	SBI 040 040 08P	SBI 040 040 13P	4.0	40	5	14
SBI 040 060 04P	SBI 040 060 08P	SBI 040 060 13P	4.0	60	5	14
SBI 040 080 04P	SBI 040 080 08P	SBI 040 080 13P	4.0	80	5	14
-	SBI 040 120 08P	SBI 040 120 13P	4.0	120	5	14
-	SBI 040 150 08P	SBI 040 150 13P	4.0	150	5	14

-	SBI04020008P	SBI04020013P	4.0	200	5	11
-	SBI04025008P	SBI04025013P	4.0	250	5	11
SBI 050 040 04P	SBI 050 040 08P	SBI 050 040 13P	5.0	40	6	14
SBI 050 060 04P	SBI 050 060 08P	SBI 050 060 04P	5.0	60	6	14
SBI 050 080 04P	SBI 050 080 08P	SBI 050 080 13P	5.0	80	6	14
-	SBI 050 120 08P	SBI 050 120 13P	5.0	120	6	14
-	SBI 050 150 08P	SBI 050 150 13P	5.0	150	6	14
-	SBI05020008P	SBI05020013P	5.0	200	6	11
-	SBI05025008P	SBI05025013P	5.0	250	6	11
SBI 060 040 04P	SBI 060 040 08P	SBI 060 040 13P	6.0	40	6	14
SBI 060 060 04P	SBI 060 060 08P	SBI 060 060 13P	6.0	60	6	14
SBI 060 080 04P	SBI 060 080 08P	SBI 060 080 13P	6.0	80	6	14
-	SBI 060 120 08P	SBI 060 120 13P	6.0	120	6	14
-	SBI 060 150 08P	SBI 060 150 13P	6.0	150	6	14
-	SBI06020008P	SBI06020013P	6.0	200	6	11
-	SBI06020008P	SBI06025013P	6.0	250	6	11
SBI 070 040 04P	SBI 070 040 08P	SBI 070 040 13P	7.0	40	7	14

SBI 070 060 04P	SBI 070 060 08P	SBI 070 060 13P	7.0	60	7	14
SBI 070 080 04P	SBI 070 080 08P	SBI 070 080 13P	7.0	80	7	14
SBI 080 040 04P	SBI 080 040 08P	SBI 080 040 13P	8.0	40	7	10
SBI 080 060 04P	SBI 080 060 08P	SBI 080 060 13P	8.0	60	7	10
SBI 080 080 04P	SBI 080 080 08P	SBI 080 080 13P	8.0	80	7	10
SBI 090 040 04P	SBI 090 040 08P	SBI 090 040 13P	9.0	40	7	10
SBI 090 060 04P	SBI 090 060 08P	SBI 090 060 13P	9.0	60	7	10
SBI 090 080 04P	SBI 090 080 08P	SBI 090 080 13P	9.0	80	7	10
SBI 100 040 04P	SBI 100 040 08P	SBI 100 040 13P	10.0	40	7	9
SBI 120 040 04P	SBI 120 040 08P	SBI 120 040 13P	12.0	40	9	9

IN.PACT™ Pacific™ Drug-Eluting Balloon⁺

Ref. Number Usable Length 90cm	Ref. Number Usable Length 130cm	Balloon Diameter (mm)	Balloon Length (mm)	Recommended Introducer Sheath (Fr)	RBP (atm)
PCF 040 040 09P	PCF 040 040 13P	4	40	5	20
PCF 040 060 09P	PCF 040 060 13P	4	60	5	14
PCF 040 080 09P	PCF 040 080 13P	4	80	5	14
PCF 040 120 09P	PCF 040 120 13P	4	120	5	14

PCF 050 040 09P	PCF 050 040 13P	5	40	5	20
PCF 050 060 09P	PCF 050 060 13P	5	60	5	14
PCF 050 080 09P	PCF 050 080 13P	5	80	5	14
PCF 050 120 09P	PCF 050 120 13P	5	120	5	14
PCF 060 040 09P	PCF 060 040 13P	6	40	5	14
PCF 060 060 09P	PCF 060 060 13P	6	60	5	16
PCF 060 080 09P	PCF 060 080 13P	6	80	5	14
PCF 060 120 09P	PCF 060 120 13P	6	120	5	14
PCF 070 040 09P	PCF 070 040 13P	7	40	6	12
PCF 070 060 09P	PCF 070 060 13P	7	60	6	12
PCF 070 080 09P	PCF 070 080 13P	7	80	6	12
PCF 070 120 09P	PCF 070 120 13P	7	120	6	12

Related pages

- [Clinical review of DCBs \(/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/performance.html\)](/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/performance.html)

- [Clinical outcomes \(/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/clinical-outcomes.html\)](/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/inpact-drug-coated-balloon/clinical-outcomes.html)
- [Paclitaxel safety \(/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/paclitaxel-safety.html\)](/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/paclitaxel-safety.html)

Technical manual

Instructions for manual use

Find this technical manual in the [Medtronic Manual Library](https://manuals.medtronic.com/manuals/main/region)(opens new window) (<https://manuals.medtronic.com/manuals/main/region>) in the product labeling supplied with each device, or by calling Medtronic at [1-763-526-7890](tel:1-763-526-7890) (tel:7635267890).

Connect with us

Reach a Medtronic sales rep

[Contact us here \(/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/request-more-information-drug-coated-balloons.html\)](/xd-en/healthcare-professionals/products/cardiovascular/drug-coated-balloons/request-more-information-drug-coated-balloons.html)

24-hour Technical Support

[1-763-514-4000](tel:1-763-514-4000) (tel:7635144000) (worldwide)
rs.cstechsupport@medtronic.com (mailto:rs.cstechsupport@medtronic.com)

*

™Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.

†

Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.

‡

Primary patency not assessed after three years.

§

Publications on file with Medtronic.

||

120, 150, 200, and 250 mm lengths are not offered on the 7.0 mm diameter balloon.

References

1

Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. *Circ Cardiovasc Interv.* June 2019;12(6):e007702.

2

Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.

3

FDA. PMA P140010: Summary of safety and effectiveness data. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010>(opens new window) (<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010>). Accessed May 23, 2022.

4

FDA. PMA P190019: Summary of safety and effectiveness data. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019>(opens new window) (<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019>). Accessed May 23, 2022.

5

Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. *Catheter Cardiovasc Interv.* January 1, 2014;83(1):132-40.

6

FDA. PMA P160049: Summary of safety and effectiveness data. Available

at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049>(opens new window)
(<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049>). Accessed May 23, 2022.

See product catalog for complete, detailed product information.



(mailto:?



body=https%3A%2F%2Feurope.
medtronic.com%2Fxd-
en%2Fhealthcare-
professionals%2Fproducts%2Fca
rdiovascular%2Fdrug-coated-
balloons%2Finpact-drug-coated-
balloon.html)

HEALTHCARE PROFESSIONALS

Overview (<https://europe.medtronic.com/xd-en/healthcare-professionals.html>)

Products (<https://europe.medtronic.com/xd-en/healthcare-professionals/products.html>)

Therapies & Procedures (<https://europe.medtronic.com/xd-en/healthcare-professionals/therapies-procedures.html>)

Integrated Health Solutions (<https://europe.medtronic.com/xd-en/healthcare-professionals/integrated-health-solutions.html>)

PATIENTS

[Overview](https://europe.medtronic.com/xd-en/your-health.html) (<https://europe.medtronic.com/xd-en/your-health.html>)

OUR COMPANY

[Who We Are](https://europe.medtronic.com/xd-en/our-company.html) (<https://europe.medtronic.com/xd-en/our-company.html>)

[Key Facts](https://europe.medtronic.com/xd-en/our-company/key-facts.html) (<https://europe.medtronic.com/xd-en/our-company/key-facts.html>)

[Leadership](https://europe.medtronic.com/xd-en/our-company/leadership.html) (<https://europe.medtronic.com/xd-en/our-company/leadership.html>)

[History](https://europe.medtronic.com/xd-en/our-company/history.html) (<https://europe.medtronic.com/xd-en/our-company/history.html>)

[Mission](https://europe.medtronic.com/xd-en/our-company/mission.html) (<https://europe.medtronic.com/xd-en/our-company/mission.html>)

[Locations](https://europe.medtronic.com/xd-en/our-company/locations.html) (<https://europe.medtronic.com/xd-en/our-company/locations.html>)

[Careers](https://europe.medtronic.com/xd-en/our-company/careers.html) (<https://europe.medtronic.com/xd-en/our-company/careers.html>)

OUR IMPACT

[Our Impact](https://europe.medtronic.com/xd-en/our-impact.html) (<https://europe.medtronic.com/xd-en/our-impact.html>)

[Healthcare access](https://europe.medtronic.com/xd-en/our-impact/healthcare-access.html) (<https://europe.medtronic.com/xd-en/our-impact/healthcare-access.html>)

[Inclusion, Diversity & Equity](https://europe.medtronic.com/xd-en/our-impact/inclusion-diversity-equity.html) (<https://europe.medtronic.com/xd-en/our-impact/inclusion-diversity-equity.html>)

[Protecting our planet](https://europe.medtronic.com/xd-en/our-impact/protecting-our-planet.html) (<https://europe.medtronic.com/xd-en/our-impact/protecting-our-planet.html>)

[ESG Report](https://europe.medtronic.com/xd-en/our-impact/esg.html) (<https://europe.medtronic.com/xd-en/our-impact/esg.html>)

[Privacy Statement](/xd-en/privacy-statement.html) (/xd-en/privacy-statement.html)

| [Terms of Use](/xd-en/terms-of-use.html) (/xd-en/terms-of-use.html)

| [Contact](https://europe.medtronic.com/xd-en/about/contact-us.html) (<https://europe.medtronic.com/xd-en/about/contact-us.html>)

UC201712493-01fEE Last Updated January 2023 © 2023 Medtronic